Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Toripalimab in Non-Muscle Invasive Bladder Neoplasms: NCT07307456 Clinical Landscape Report 2026
28 September 2026
NCT07307456 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Cretostimogene Grenadenorepvec in Non-Muscle Invasive Bladder Neoplasms: NCT07283835 Clinical Landscape Report 2026
28 September 2026
NCT07283835 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Tislelizumab in HER2 Positive Muscle Invasive Bladder Carcinoma: NCT07296705 Clinical Landscape Report 2026
28 September 2026
NCT07296705 clinical landscape for HER2 Positive Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
BCT301 Cell(Peking University Third Hospital) in Idiopathic Inflammatory Myopathies: NCT07301164 Clinical Landscape Report 2026
28 September 2026
NCT07301164 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
SHR-2173 in Systemic Lupus Erythematosus: NCT07299422 Clinical Landscape Report 2026
28 September 2026
NCT07299422 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(The Children's Hospital of Zhejiang University School of Medicine) in Granulomatosis With Polyangiitis: NCT07305116 Clinical Landscape Report 2026
28 September 2026
NCT07305116 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
HC022 in Lupus Erythematosus, Cutaneous: NCT07306585 Clinical Landscape Report 2026
28 September 2026
NCT07306585 clinical landscape for Lupus Erythematosus, Cutaneous: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nomelcitinib in Systemic Lupus Erythematosus: NCT07311200 Clinical Landscape Report 2026
28 September 2026
NCT07311200 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trastuzumab Rezetecan in Locally Advanced Malignant Solid Neoplasm: NCT07309770 Clinical Landscape Report 2026
28 September 2026
NCT07309770 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences) in Idiopathic Inflammatory Myopathies: NCT07315087 Clinical Landscape Report 2026
28 September 2026
NCT07315087 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Gemcitabine Hydrochloride in Urothelial Carcinoma of the Urinary Bladder: NCT07322263 Clinical Landscape Report 2026
28 September 2026
NCT07322263 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Gemcitabine Hydrochloride/Docetaxel in Urothelial Carcinoma of the Urinary Bladder: NCT07313891 Clinical Landscape Report 2026
28 September 2026
NCT07313891 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…